Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0001209191-23-045595

Chief Financial Officer sold 682 shares at $2.36 ($1,610)

  • Chief Financial Officer acquired 2,292 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Delfini Lisa Chief Financial Officer 2023-08-11 Option exercise 10b5-1 +2,292 $0.51 $1,171 33,496 D
Delfini Lisa Chief Financial Officer 2023-08-11 Sale 10b5-1 −682 $2.36 $1,610 32,814 D
Derivatives
Delfini Lisa Chief Financial Officer 2023-08-11 Option exercise · Stock Option (right to buy) 10b5-1 −2,292 68,751 D
Open-market sales · 682 sh · avg $2.36 · $1,610
Loading xslF345X05/doc4.xml…